Cooperative Learning: The Teacher\u27s Perspective

This dissertation is an inquiry into what happens when classroom teachers in public schools study and adopt one or more of the cooperative learning models of David and Roger Johnson, Spencer Kagan, and/or Robert Slavin and shift the emphasis of their classrooms from competitive and individualistic to cooperative structures. Method: A representative sample of eighteen kindergarten through twelfth grade public school teachers from the suburbs of Boston were asked to relate their experiences with training and implementation of these cooperative models. The goal of this research was to explore both the common and unique experiences of these teachers and to discover whether they experienced significant shifts in their personal philosophies of teaching, teaching practices, and interactions with others in the school community. In these interviews, teachers who were trained in cooperative paradigms told the story of their training, implementation, experiences with others in their school community, and personal reflections. The inquiry was set in the context of school reform movements that explore the ways in which individuals make meaning from both professional and life experiences. Results: The interviews were analyzed using HyperResearch, a qualitative research computer program. A framework for analysis of the interviews in this study was derived from the literatures of the study of cooperative, competitive, and individualistic paradigms; professional development; and school reform. The teachers in the study were found to be undergoing paradigm shifts on a continuum of change. Training, time, and support from their educational community were factors that appeared to influence the most dramatic shifts in their practice and points of view. Conclusions: Teachers interpret training they receive in cooperative learning programs in ways that are specifically related to their own professional development and their teaching environments. Yet, they experience some common difficulties and successes. Since the adoption of cooperative learning models ultimately influences teachers\u27 cognitive development and necessitates a paradigm shift from competitive and individual structures to cooperative ones, this process is dependent on a long period of commitment and sustained practice. The support teachers receive from their school community and peers facilitates or impedes their implementation and utilization of cooperative paradigms. The larger school and societal context ultimately determines the influence cooperative classrooms will have on students and teachers alike

The PAPAGENO Parallel-Parser Generator

The increasing use of multicore processors has deeply transformed computing paradigms and applications. The wide availability of multicore systems had an impact also in the field of compiler technology, although the research on deterministic parsing did not prove to be effective in exploiting the architectural advantages, the main impediment being the inherent sequential nature of traditional LL and LR algorithms. We present PAPAGENO, an automated parser generator relying on operator precedence grammars. We complemented the PAPAGENO-generated parallel parsers with parallel lexing techniques, obtaining near-linear speedups on multicore machines, and the same speed as Bison parsers on sequential execution

Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2

Amyotrophic lateral sclerosis is a fatal neurodegenerative disease causing upper and lower motor neuron loss and currently no effective disease-modifying treatment is available. A pathological feature of this disease is neuroinflammation, a mechanism which involves both CNS-resident and peripheral immune system cells. Regulatory T-cells are immune-suppressive agents known to be dramatically and progressively decreased in patients with amyotrophic lateral sclerosis. Low-dose interleukin-2 promotes regulatory T-cell expansion and was proposed as an immune-modulatory strategy for this disease. A randomized placebo-controlled pilot phase-II clinical trial called Immuno-Modulation in Amyotrophic Lateral Sclerosis was carried out to test safety and activity of low-dose interleukin-2 in 36 amyotrophic lateral sclerosis patients (NCT02059759). Participants were randomized to 1MIU, 2MIU-low-dose interleukin-2 or placebo and underwent one injection daily for 5 days every 28 days for three cycles. In this report, we describe the results of microarray gene expression profiling of trial participants' leukocyte population. We identified a dose-dependent increase in regulatory T-cell markers at the end of the treatment period. Longitudinal analysis revealed an alteration and inhibition of inflammatory pathways occurring promptly at the end of the first treatment cycle. These responses are less pronounced following the end of the third treatment cycle, although an activation of immune-regulatory pathways, involving regulatory T-cells and T helper 2 cells, was evident only after the last cycle. This indicates a cumulative effect of repeated low-dose interleukin-2 administration on regulatory T-cells. Our analysis suggested the existence of inter-individual variation amongst trial participants and we therefore classified patients into low, moderate and high-regulatory T-cell-responders. NanoString profiling revealed substantial baseline differences between participant immunological transcript expression profiles with the least responsive patients showing a more inflammatory-prone phenotype at the beginning of the trial. Finally, we identified two genes in which pre-treatment expression levels correlated with the magnitude of drug responsiveness. Therefore, we proposed a two-biomarker based regression model able to predict patient regulatory T-cell-response to low-dose interleukin-2. These findings and the application of this methodology could be particularly relevant for future precision medicine approaches to treat amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2

Amyotrophic lateral sclerosis is a fatal neurodegenerative disease causing upper and lower motor neuron loss and currently no effective disease-modifying treatment is available. A pathological feature of this disease is neuroinflammation, a mechanism which involves both CNS-resident and peripheral immune system cells. Regulatory T-cells are immune-suppressive agents known to be dramatically and progressively decreased in patients with ALS. Low-dose interleukin-2 promotes regulatory T-cell expansion and was proposed as an immune-modulatory strategy for this disease. A randomized placebo-controlled pilot phase-II clinical trial called Immuno-Modulation in Amyotrophic Lateral Sclerosis (IMODALS) was carried out to test safety and activity of low-dose interleukin-2 in 36 amyotrophic lateral sclerosis patients (NCT02059759). Participants were randomized to 1MIU, 2MIU-low-dose interleukin-2 or placebo and underwent one injection daily for five days every twenty-eight days for three cycles. In this report, we describe the results of microarray gene expression profiling of trial participants' leukocyte population. We identified a dose-dependent increase in regulatory T-cell markers at the end of the treatment period. Longitudinal analysis revealed an alteration and inhibition of inflammatory pathways occurring promptly at the end of the first treatment cycle. These responses are less pronounced following the end of the third treatment cycle, although an activation of immune-regulatory pathways, involving regulatory T-cells and T helper 2 cells, was evident only after the last cycle. This indicates a cumulative effect of repeated low-dose interleukin-2 administration on regulatory T-cells. Our analysis suggested the existence of inter-individual variation amongst trial participants and we therefore classified patients into low, moderate and high-Treg-responders. NanoString profiling revealed substantial baseline differences between participant immunological transcript expression profiles with the least responsive patients showing a more inflammatory-prone phenotype at the beginning of the trial. Finally, we identified two genes in which pre-treatment expression levels correlated with the magnitude of drug responsiveness. Therefore, we proposed a two-biomarker based regression model able to predict patient Treg-response to low-dose interleukin-2. These findings and the application of this methodology could be particularly relevant for future precision medicine approaches to treat amyotrophic lateral sclerosis

Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS

This work was supported by the José Luis Castaño Foundation, Spain (LLL)